This past year has been a milestone in diagnostic advancements, with significant strides in dPCR, multiplex PCR testing, and immunoassay-based detection. As we enter 2024, we are excited to share the emerging trends and technological progress in areas of compact and affordable point-of-care solutions on par with core lab standards and leverage our wet lab and data analytics proficiency to fast-track new product development, marking another year of positively impacting Diagnostics and Life Science industry.
In 2023, we were privileged to share numerous significant insights with you. Throughout the year, our newsletter has served as a platform for discussing groundbreaking developments and innovative solutions in diagnostics. We have delved into areas like dPCR, multiplexed PCR, and single molecule counting-based immunoassay for the early detection of diseases, highlighting the current challenges and our solutions.
We have developed innovative solutions to tackle digital PCR (dPCR) challenges by leveraging our expertise in fluorescence imaging, cost-efficient design, and technology platforms. Our approach focuses on accurate fluorescence detection and minimizing errors, which is crucial in dPCR for counting target molecules in a sample. Through optimizing optical design and offering complete, efficient imaging systems, Volpi enhances the accuracy and speed of dPCR, thereby streamlining diagnostic processes in Life Sciences. Read the full article here.
Our technology has been a game-changer in the realm of “syndromic” multiplex PCR testing, a pivotal tool for rapid respiratory virus diagnostics. It significantly reduces hospital stays and healthcare costs by offering faster results. However, implementing this technology, particularly in Point-Of-Care (POC) settings, presents challenges and guaranteeing lab precision with a low-cost and compact system requires a proper design. Volpi addresses these challenges with its expertise in multiplex PCR instrumentation, offering solutions with the best performance to cost, reducing development time, and catering to diverse market needs. Read the full article here.
Lastly, our strides in immunoassays, particularly in achieving femtomolar sensitivity for early disease detection, face significant challenges in single molecule detection due to nonspecific binding (NSB) and background noise. We are addressing these issues with our customers and are helping them bring reliable solutions to the market rapidly and efficiently. Addressing the complexities of these assays, we offer tailored, plug-and-play solutions that enhance detection sensitivity and reduce development risks, leveraging our expertise in optics-based measuring systems for IVD and Life Sciences. Read the full article here.
We are proud to share these advancements with you, our newsletter readers. Our commitment to overcoming technical challenges in IVD and Life Sciences continues to drive us towards more sensitive, specific, and rapid medical testing solutions, reinforcing our role as a key enabler in the industry. In 2024, we intend to share the latest advancements in our capabilities, exciting new offerings, and industry trends. Anticipate in-depth insights on our application testing and data analytics expertise and how they are used to enable real-time feedback in customer programs to accelerate and de-risk
Alexandre Larmagnac, Ph.D.
Head of Application and Sales Support